| 序号 | 专利名 | 申请号 | 申请日 | 公开（公告）号 | 公开（公告）日 | 发明人 |
|---|---|---|---|---|---|---|
| 181 | Thrombolytic enzyme and a process for its preparation | US10849229 | 2004-05-20 | US07776574B2 | 2010-08-17 | Perurmadom Ramaiyer Mahadevan; Subrahmanyam Chivukula Sekar; Sundaramurthy Suresh Babu |
| The invention relates to a thrombolytic enzyme referred to as Thrombinase having a molecular weight of 31,000 to 32,000. Such a thrombolytic enzyme can be used for dissolving blood clots. The process comprises culturing a filtrate of Bacillus sphaericus sero type H5a 5b, removing the cell, subjecting the cell supernatant to filtration, salting out the retentate, subjecting the precipitate to dialysis, reprecipitating the precipitate and then reconstituting in buffer and finally decolourizing, purifying and dialyzing. | ||||||
| 182 | Methods of Therapy and Diagnosis Using Immunotargeting of CD84Hy1-expressing Cells | US12099621 | 2008-04-08 | US20090053136A1 | 2009-02-26 | Douglas Dedera; Jian-Rui Wang; Peter C.R. Emtage |
| Certain cells, including types of cancer cells such as lymphomas, are capable of expressing high levels of CD84Hy1. Immunotargeting using CD84Hy1 polypeptides, nucleic acids encoding for CD84Hy1 polypeptides and anti-CD84Hy1 antibodies provides a method of killing or inhibiting that growth of CD84HY1 Protein-expressing cancer cells. Methods of immunotherapy and diagnosis of disorders associated with CD84Hy1 protein-expressing cells are described. | ||||||
| 183 | Methods and Materials Relating to CD84-like Polypeptides and Polynucleotides | US12100713 | 2008-04-10 | US20090042199A1 | 2009-02-12 | Chiaoyun Kuo; Bryan J. Boyle; Jian-Rui Wang; Y. Tom Tang; Chenghua Liu; Radoje T. Drmanac |
| The invention provides novel polynucleotides and polypeptides encoded by such polynucleotides and mutants or variants thereof that correspond to a novel human secreted CD84-like polypeptide. These polynucleotides comprise nucleic acid sequences isolated from cDNA library from human spleen (Hyseq clone identification numbers 2938352 (SEQ ID NO: 1)). Other aspects of the invention include vectors containing processes for producing novel human secreted CD84-like polypeptides, and antibodies specific for such polypeptides. | ||||||
| 184 | RNA APTAMERS AND METHODS FOR IDENTIFYING THE SAME | US11925641 | 2007-10-26 | US20080182809A1 | 2008-07-31 | Bruce A. Sullenger; Christopher P. Rusconi |
| RNA aptamers and methods for identifying the same are disclosed. The RNA aptamers selectively bind coagulation factors, E2F family members, Ang1 or Ang2, and therapeutic and other uses for the RNA aptamers are also disclosed. | ||||||
| 185 | Methods of therapy and diagnosis using immunotargeting of CD84Hy1-expressing cells | US11330768 | 2006-01-11 | US07378253B2 | 2008-05-27 | Douglas Dedera; Jian Rui Wang; Peter Emtage |
| Certain cells, including types of cancer cells such as lymphomas, are capable of expressing high levels of CD84Hy1. Immunotargeting using CD84Hy1 polypeptides, nucleic acids encoding for CD84Hy1 polypeptides and anti-CD84Hy1 antibodies provides a method of killing or inhibiting that growth of CD84HY1Protein-expressing cancer cells. Methods of immunotherapy and diagnosis of disorders associated with CD84Hy1 protein-expressing cells are described. | ||||||
| 186 | Stem cell growth factor-like polypeptides | US10968674 | 2004-10-19 | US07319141B2 | 2008-01-15 | Y. Tom Tang; Ivan Labat; Radoje T. Drmanac; Nancy K. Mize; Mitsuo Nishikawa; Cheng-Chi Chao |
| The invention provides novel polynucleotides and polypeptides encoded by such polynucleotides and mutants or variants thereof that correspond to a novel human stem cell growth factor-like protein. These polynucleotides comprise nucleic acid sequences isolated from cDNA libraries from human testis cells (Hyseq clone identification numbers 2880984 and 2881695), from human fetal skin (Hyseq clone identification number 15375176), adult spleen (Hyseq clone identification number 14856094), and human endothelial cells (Hyseq clone identification numbers 13804756, 13687487, 13804756). Other aspects of the invention include vectors containing processes for producing novel human stem cell growth factor-like polypeptides, and antibodies specific for such polypeptides. | ||||||
| 187 | DIAFILTRATION SYSTEM TO FRACTIONATE PROTEIN MIXTURES | US11683029 | 2007-03-07 | US20080009443A1 | 2008-01-10 | Howard Purdum |
| The present invention provides a method for the separation of proteins on the basis of molecular weight by use of a multi-segment fractionation chamber based on the principles of diafiltration. In addition, the present invention provides an effective method for the concentration of plasma and recovery of fractions thereof that contain immune factors, clotting factors, and/or albumin. The present invention also provides a plasma diafiltration system and apparatus for the safe preparation of clotting factor concentrates that have broad and practical application to surgery or trauma patients, and patients lacking clotting factors due to inherited diseases or other complication. | ||||||
| 188 | RNA aptamers and methods for identifying the same | US09963827 | 2001-09-26 | US07312325B2 | 2007-12-25 | Bruce A. Sullenger; Christopher P. Rusconi |
| RNA aptamers and methods for identifying the same are disclosed. The RNA aptamers selectively bind coagulation factors, E2F family members, Ang1 or Ang2, and therapeutic and other uses for the RNA aptamers are also disclosed. | ||||||
| 189 | Nucleic acids encoding factor X analogues having a modified protease cleavage site | US10407123 | 2003-04-04 | US07220569B2 | 2007-05-22 | Michele Himmelspach; Uwe Schlokat; Friedrich Dorner; Andreas Fisch; Johann Eibl |
| Nucleic acids encoding factor X analogues are provided that have a modification in the region of the natural Factor Xa activation cleavage site. The modification results in a processing site for a protease not naturally cleaving in this region of the Factor X sequence. | ||||||
| 190 | Insect expression vectors | US09896888 | 2001-06-29 | US07135337B2 | 2006-11-14 | Tom A. Grigliatti; Tom A. Pfeifer; David A. Theilmann; Dwayne D. Hegedus |
| The invention provides insect shuttle vectors, and methods of using such vectors, for stably transforming disparate insect cell lines to express heterologous proteins. The invention provides a transformed insect cell selection system based on resistance to the bleomycin/phleomycin family of antibiotics, including the antibiotic Zeocin. Efficient promoters derived from baculovirus immediate early promoters are disclosed for use in directing expression of heterologous proteins, including selectable markers, in transformed insect cells of the invention. Transposon-based vectors are disclosed that provide inducible transposition to optimize heterologous protein expression and unobtrusive markers to facilitate selection of desired transformants. | ||||||
| 191 | Thrombin cleavable factor x analogues | US10518390 | 2003-06-30 | US20060148038A1 | 2006-07-06 | Virginie Louvain; Elsa Bianchini; Pierre-Emmanuel Marque; Claire Calmel-Tareau; Martine Aiach; Bernard Le Bonniec |
| The invention relates to factor X analogues containing the thrombin-cleavable sequence Pro-Arg-Ala in place of the-sequence Thr-Arg-Ile of the activation site of native factor X. These factor X analogues can be used to obtain procoagulant medicinal products. | ||||||
| 192 | Methods and materials relating to novel growth regulatory-like polypeptides and polynucleotides | US11002174 | 2004-12-02 | US20050153334A1 | 2005-07-14 | Nancy Mize; Bryan Boyle; John Ford; Matthew Arterburn; Y. Tang; Chenghua Liu; Radoje Drmanac; Yong Song; Michael Sjaastad |
| The invention provides novel polynucleotides and polypeptides encoded by such polynucleotides and mutants or variants thereof that correspond to a novel human growth regulatory-like polypeptide. These polynucleotides comprise nucleic acid sequences isolated from cDNA libraries from human thymus (Hyseq clone identification number 16372272). Other aspects of the invention include vectors containing processes for producing novel human growth regulatory-like polypeptides, and antibodies specific for such polypeptides. | ||||||
| 193 | Method of purifying calcium ion-binding protein | US10088588 | 2001-07-18 | US06869934B2 | 2005-03-22 | Hiroshi Mizokami; Shinichi Furukawa; Keishin Sugawara; Tatsufumi Onchi; Kazuhiro Komatsu; Satoshi Koyanagi; Hideo Yoshizaki |
| The present invention relates to a method for purifying a calcium ion-binding protein by cation exchange chromatography. The present invention provide a method for isolating and purifying a calcium ion-binding protein in a simple and efficient manner from a liquid sample containing a calcium ion-binding protein and contaminants without any pretreatment such as addition of a chelating agent. More specifically, the present invention relates to a method for purifying a calcium ion-binding protein which comprises contacting said protein with a cation exchange carrier in the presence of calcium ions to let the said protein be adsorbed to the carrier, and after washing, eluting said protein, and to a calcium ion-binding protein having substantially no contaminants obtained by the method of the present invention. | ||||||
| 194 | Method for purifying calcium ion-binding protein | US10944810 | 2004-09-21 | US20050059805A1 | 2005-03-17 | Hiroshi Mizokami; Shinichi Furukawa; Keishin Sugawara; Tatsufumi Onchi; Kazuhiro Komatsu; Satoshi Koyanagi; Hideo Yoshizaki |
| The present invention relates to a method for purifying a calcium ion-binding protein by cation exchange chromatography. The present invention provide a method for isolating and purifying a calcium ion-binding protein in a simple and efficient manner from a liquid sample containing a calcium ion-binding protein and contaminants without any pretreatment such as addition of a chelating agent. More specifically, the present invention relates to a method for purifying a calcium ion-binding protein which comprises contacting said protein with a cation exchange carrier in the presence of calcium ions to let the said protein be adsorbed to the carrier, and after washing, eluting said protein, and to a calcium ion-binding protein having substantially no contaminants obtained by the method of the present invention. | ||||||
| 195 | Methods and materials relating to semaphorin-like polynucleotides | US10461791 | 2003-06-12 | US06818754B1 | 2004-11-16 | Bryan J. Boyle; George Yeung; Matthew C. Arterburn; Nancy K. Mize; Y. Tom Tang; Chenghua Liu; Radoje T. Drmanac |
| The invention provides novel polynucleotides and polypeptides encoded by such polynucleotides and mutants or variants thereof that correspond to a novel human secreted semaphorin-like polypeptide. These polynucleotides comprise nucleic acid sequences isolated from cDNA library from fetal liver-spleen (Hyseq clone identification numbers 5688868 (SEQ ID NO: 1)). Other aspects of the invention include vectors containing processes for producing novel human secreted semaphorin-like polypeptides, and antibodies specific for such polypeptides. | ||||||
| 196 | Methods and materials relating to soluble transforming growth factor alpha-like polypeptides and polynucleotides | US10311828 | 2004-03-01 | US20040132022A1 | 2004-07-08 | Bryan J. Boyle; Nancy K. Mize; Matthew C. Arterburn; Servando Palencia; Y Tom Tang; Chenghua Liu; Radoje T. Drmanac; Ivan Labat; Birgit Stache-Crain; Kody Nguyen; Veronica E. Garcia |
| The invention provides novel polynucleotides and polypeptides encoded by such polynucleotides and mutants or variants thereof that correspond to a novel human secreted TGF alpha-like polypeptide. These polynucleotides comprise nucleic acid sequences isolated from cDNA library from human adult kidney (Hyseq clone identification number 16441036). Other aspects of the invention include vectors containing processes for producing novel human secreted TGF alpha-like polypeptides, and antibodies specific for such polypeptides. | ||||||
| 197 | Binding agents to CD23 | US10632852 | 2003-08-04 | US20040022783A1 | 2004-02-05 | Jean-Yves Marcel Paul Bonnefoy |
| The present invention relates to agents that bind CD23 and that can be used in the treatment of inflammatory, autoimmune or allergic diseases. | ||||||
| 198 | Nucleic acid construct for expressing active substances which can be activated by proteases, and preparation and use | US09256237 | 1999-02-24 | US06670147B1 | 2003-12-30 | Hans Heinrich Heidtmann; Rolf Mueller; Hans-Harald Sedlacek |
| The invention relates to a nucleic acid construct for expressing an active substance which is activated by an enzyme which is released from mammalian cells, which construct comprises the following components: a) at least one promoter element, b) at least one DNA sequence which encodes an active compound (protein B), c) a least one DNA sequence which encodes an amino acid sequence (part structure C) which can be cleaved specifically by an enzyme which is released from a mammalian cell, and d) at least one DNA sequence which encodes a peptide or protein (part structure D) which is bound to the active compound (protein B) by way of the cleavable amino acid sequence (part structure C) and inhibits the activity of the active compound (protein B), and also to the use of the nucleic acid construct for preparing a drug for treating diseases. | ||||||
| 199 | Novel nucleic acids and polypeptides | US10291172 | 2002-11-08 | US20030228584A1 | 2003-12-11 | Y. Tom Tang; Chenghua Liu; Vinod Asundi; Rui-Hong Chen; Yunqing Ma; Feiyan Ren; Jian-Rui Wang; Tom Wehrman; Chongjun Xu; Aidong J. Xue; Yonghong Yang; Jie Zhang; Qing A. Zhao; Ping Zhou; Radoje T. Drmanac |
| The present invention provides novel nucleic acids, novel polypeptide sequences encoded by these nucleic acids and uses thereof | ||||||
| 200 | Enhanced gamma-carboxylation of recombinant vitamin K-dependent clotting factors | US10349858 | 2003-01-22 | US20030220247A1 | 2003-11-27 | Katherine A. High; Rodney M. Camire; Peter J. Larson; Darrel W. Stafford |
| The invention relates to methods of optimizing gamma carboxylation of a vitamin K-dependent protein, methods of generating fully gamma carboxylated vitamin K-dependent protein, and compositions comprising chimeric nucleic acids and proteins for use in treatment of vitamin K-dependent disease states. | ||||||
QQ群二维码
意见反馈
意见反馈